Neogenomics Inc
NASDAQ:NEO

Watchlist Manager
Neogenomics Inc Logo
Neogenomics Inc
NASDAQ:NEO
Watchlist
Price: 6.91 USD 0.14% Market Closed
Market Cap: 889.2m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one NEO stock under the Base Case scenario is 20.99 USD. Compared to the current market price of 6.91 USD, Neogenomics Inc is Undervalued by 67%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NEO Relative Value
Base Case
20.99 USD
Undervaluation 67%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.3
P/S
P/S
Price to Sales
1.3
vs History
98
vs Industry
69
Median 3Y
2.9
Median 5Y
3.5
Industry
4
Forward
1.2
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
100
Median 3Y
-17.8
Median 5Y
-18.2
Industry
31.4
Forward
43
More Details
116.5
P/OCF
P/OCF
Price to OCF
116.5
vs History
41
vs Industry
1
Median 3Y
-17.3
Median 5Y
-17.2
Industry
19.5
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-30.5
Median 5Y
-15.8
Industry
33.5
More Details
1
P/B
P/B
Price to Book Value
1
vs History
95
vs Industry
62
Median 3Y
1.9
Median 5Y
2.2
Industry
2.7
More Details
1.3
EV/S
EV/S
Enterprise Value to Sales
1.3
vs History
98
vs Industry
68
Median 3Y
3.1
Median 5Y
3.7
Industry
3.8
Forward
1.2
More Details
2.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.9
vs History
98
vs Industry
67
Median 3Y
7.6
Median 5Y
8.9
Industry
8.4
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
4
Median 3Y
-70
Median 5Y
-43.9
Industry
17.5
Forward
15.5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-17.9
Median 5Y
-20.5
Industry
23.6
Forward
-11.2
More Details
114.3
EV/OCF
EV/OCF
Enterprise Value to OCF
114.3
vs History
41
vs Industry
1
Median 3Y
-18.2
Median 5Y
-18.2
Industry
18.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-34.3
Median 5Y
-51.4
Industry
23.5
More Details
0.7
EV/IC
EV/IC
Enterprise Value to IC
0.7
vs History
98
vs Industry
66
Median 3Y
1.5
Median 5Y
1.7
Industry
2.4
More Details

Multiples Across Competitors

NEO Competitors Multiples
Neogenomics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Neogenomics Inc
NASDAQ:NEO
886.9m USD 1.3 -11.4 -66.4 -10.2
US
PerkinElmer Inc
LSE:0KHE
1T USD 375.7 3 631.2 1 273.2 2 597
US
Thermo Fisher Scientific Inc
NYSE:TMO
157.2B USD 3.7 24.1 16.9 23.3
US
Danaher Corp
NYSE:DHR
138.3B USD 5.8 36.7 20.3 29.5
KR
Samsung Biologics Co Ltd
KRX:207940
71.2T KRW 14.5 55.6 32.3 44.9
CH
Lonza Group AG
SIX:LONN
39.8B CHF 6.1 62.4 22.9 35.8
CN
WuXi AppTec Co Ltd
SSE:603259
227.6B CNY 5.6 20.4 19.7 19.7
US
Agilent Technologies Inc
NYSE:A
32.2B USD 4.9 27.6 18.8 22.1
US
IQVIA Holdings Inc
NYSE:IQV
27.6B USD 1.8 20.7 11.5 17.1
US
Mettler-Toledo International Inc
NYSE:MTD
24.6B USD 6.4 29 21.5 23.9
FR
Sartorius Stedim Biotech SA
PAR:DIM
18.9B EUR 6.6 92 29.6 52.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Neogenomics Inc
NASDAQ:NEO
Average EV/EBITDA: 146.7
Negative Multiple: -66.4 		N/A N/A
US
P
PerkinElmer Inc
LSE:0KHE
1 273.2
7%
181.9
US
Thermo Fisher Scientific Inc
NYSE:TMO
16.9
6%
2.8
US
Danaher Corp
NYSE:DHR
20.3
7%
2.9
KR
Samsung Biologics Co Ltd
KRX:207940
32.3
17%
1.9
CH
Lonza Group AG
SIX:LONN
22.9
18%
1.3
CN
WuXi AppTec Co Ltd
SSE:603259
19.7
24%
0.8
US
Agilent Technologies Inc
NYSE:A
18.8
10%
1.9
US
IQVIA Holdings Inc
NYSE:IQV
11.5
9%
1.3
US
Mettler-Toledo International Inc
NYSE:MTD
21.5
4%
5.4
FR
Sartorius Stedim Biotech SA
PAR:DIM
29.6
20%
1.5

See Also

Summary
NEO intrinsic value, competitors valuation, and company profile.
DCF Valuation
NEO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NEO stock valuation using valuation multiples.
Wall Street Estimates
NEO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NEO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 268,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.